In 30 years gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers
Lehtinen M, Gray P, Louvanto K, Vänskä S.
Julkaisut
2022
Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
Mühr LSA, Eklund C, Lagheden C, Eriksson T, Pimenoff VN, Gray P, Lehtinen M, Dillner J.
Association of Chlamydia trachomatis infection with cervical atypia in adolescent women with short-term or long-term use of oral contraceptives: a longitudinal study in HPV vaccinated women
Adhikari I, Eriksson T, Harjula K, Hokkanen M, Apter D, Nieminen P, Luostarinen T, Lehtinen M.
2021
Moral dilemma(s) in human papillomavirus vaccination - revisiting the role of the herd effect.
Lehtinen M, Pimenoff VN.
Elimination of HPV-associated oropharyngeal cancers in Nordic countries
Lehtinen T, Elfström KM, Mäkitie A, Nygård M, Vänskä S, Pawlita M, Dillner J, Waterboer T, Lehtinen M.
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
Mariz FC, Gray P, Bender N, Eriksson T, Kann H, Apter D, Paavonen J, Pajunen E, Prager KM, Sehr P, Surcel HM, Waterboer T, Müller M, Pawlita M, Lehtinen M.
Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial
Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, Surcel HM, Faust H, Dillner J, Lehtinen M.
Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial
Kalliala I, Eriksson T, Aro K, Hokkanen M, Lehtinen M, Gissler M, Nieminen P.
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort
Kann H, Lehtinen M, Eriksson T, Surcel HM, Dillner J, Faust H.
Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland
Lehtinen M, Apter D, Eriksson T, Harjula K, Hokkanen M, Natunen K, Nieminen P, Paavonen J, Palmroth J, Petäjä T, Pukkala E, Vänskä S, Cheuvart B, Soila M, Bi D, Struyf F.
Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study
Tota JE, Struyf F, Hildesheim A, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, Porras C, Schiffman M, Schiller JT, Quint W, Kreimer AR, Lehtinen M, Wheeler CM, Sampson JN.
Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs
Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs
Human exposome assessment platform
Merino Martinez R, Müller H, Negru S, Ormenisan A, Arroyo Mühr LS, Zhang X, Trier Møller F, Clements MS, Kozlakidis Z, Pimenoff VN, Wilkowski B, Boeckhout M, Öhman H, Chong S, Holzinger A, Lehtinen M, van Veen EB, Bała P, Widschwendter M, Dowling J, Törnroos J, Snyder MP, Dillner J.
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Bly A, Gray P, Harjula K, Heikkilä K, Hokkanen M, Karttunen H, Kuortti M, Nieminen P, Nummela M, Paavonen J, Palmroth J, Petäjä T, Pukkala E, Soderlund-Strand A, Veivo U, Dillner J
2020
Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied.
Vänskä S, Luostarinen T, Bausssano I, Apter D, Eriksson T, Natunen K, Nieminen P, Paavonen J, Pimenoff VN, Pukkala E, Söderlund-Strand A, Dubin G, Garnett G, Dillner J, Lehtinen M.
Human papillomavirus genotype replacement: still too early to tell?
Man I, Vänskä S, Lehtinen M, Bogaards JA.
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.
Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, Prabhu PR, Sankaranarayanan R, Eriksson T, Pawlita M, Prager K, Sehr P, Waterboer T, Müller M, Lehtinen M.
Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project
Braeye, T., Emborg, H. D., Llorente-García, A., Huerta, C., Martín-Merino, E., Duarte-Salles, T., Danieli, G., Tramontan, L., Weibel, D., McGee, C., Villa, M., Gini, R., Lehtinen, M., Titievsky, L., & Sturkenboom, M.
Impact of HPV vaccination on cervical screening performance: A population-based cohort study
Lei, J., Ploner, A., Lehtinen, M., Sparén, P., Dillner, J., & Elfström, K. M.
Long-term follow-up of human papillomavirus (HPV) type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage
Gray, P., Kann, H., Pimenoff, V. N., Adhikari, I., Eriksson, T., Surcel, H. M., Vänskä, S., Dillner, J., Faust, H., & Lehtinen, M.
The age-specific cervical cancer incidence differs between human papillomavirus types: Implications for predicting the impact of elimination programs
Vänskä S, Luostarinen T, Lagheden C, Eklund C, Kleppe SN, Andrae B, Sparén P, Sundström K, Lehtinen M, Dillner J.
Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials
Tota JE, Struyf F, Hildesheim A, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, Porras C, Schiffman M, Schiller JT, Quint W, Kreimer AR, Lehtinen M, Wheeler CM, Sampson JN; Costa Rica Vaccine Trial and PATRICIA study.
Sustained cross-reactive antibody responses after human papillomavirus vaccinations: up to 12 years follow-up in the Finnish Maternity Cohort.
Kann H, Lehtinen M, Eriksson T, Surcel HM, Dillner J, Faust H.
Determinants of human papillomavirus vaccine uptake by adult women attending cervical cancer screening in 9 European countries
Robles C, Bruni L, Acera A, Riera JC, Prats L, Poljak M, Mlakar J, Oštrbenk Valenčak A, Eriksson T, Lehtinen M, Louvanto K, Hortlund M, Dillner J, Faber MT, Munk C, Kjaer SK, Petry KU, Denecke A, Xu L, Arbyn M, Cadman L, Cuzick J, Dalstein V, Clavel C, de Sanjosé S, Bosch FX.
2019
Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies
Lehtinen M, Baussano I, Paavonen J, Vänskä S, Dillner J.
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort
Artemchuk H, Eriksson T, Poljak M, Surcel HM, Dillner J, Lehtinen M, Faust H.
Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)
Gray P, Luostarinen T, Vänskä S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund-Strand A, Dillner J, Lehtinen M.
Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.
Aro K, Nieminen P, Louvanto K, Jakobsson M, Virtanen S, Lehtinen M, Dillner J, Kalliala I
Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females – results from a community‐randomized trial
Lehtinen M, Apter D, Eriksson T, Harjula K, Hokkanen M, Lehtinen T, Natunen K, Damaso S, Soila M, Bi D, Struyf F.
The Prevalence of HSV, HHV-6, HPV and Mycoplasma genitalium in Chlamydia trachomatis positive and Chlamydia trachomatis Negative Urogenital Samples among Young Women in Finland.
Korhonen S, Hokynar K, Eriksson T, Natunen K, Paavonen J, Lehtinen M, Puolakkainen M.
Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D, Apter D, Eriksson T, Hokkanen M, Zima J, Damaso S, Soila M, Dubin G, Lehtinen M, Struyf F.
2018
Which human papillomavirus vaccine and vaccination strategy for national programs?
Lehtinen M.
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)
Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, Garnett G.
The risk of cervical atypia in oral contraceptive users.
Adhikari I, Eriksson T, Luostarinen T, Lehtinen M, Apter D.
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, Söderlund-Strand A, Vänskä S, Paavonen J, Pukkala E, Dillner J, Lehtinen M.
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Dillner J, Dubin G, Garnett G.
2017
Vaccination protects against invasive HPV-associated cancers.
Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, Paavonen J, Pukkala E, Lehtinen M.
Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination.
Lehtinen T, Söderlund-Strand A, Petäjä T, Eriksson T, Jokiranta S, Natunen K, Dillner J, Lehtinen M.
Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
Baussano I, Lazzarato F, Ronco G, Lehtinen M, Dillner J, Franceschi S.
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.
Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, Pukkala E, Siitari-Mattila M, Struyf F, Nieminen P, Paavonen J, Dubin G, Dillner J.
Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort.
Lehtinen M, Surcel HM, Natunen K, Pukkala E, Dillner J.
2016
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, Pukkala E, Angelo MG, Zima J, David MP, Datta S, Bi D, Struyf F, Dubin G.
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Limson G, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Del Rosario-Raymundo MR, Catteau G, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.
2015
Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M, Apter D.
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial
Lehtinen M, Apter D, Baussano I, Eriksson T, Natunen K, Paavonen J, Vänskä S, Bi D, David MP, Datta S, Struyf F, Jenkins D, Pukkala E, Garnett G, Dubin G.
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.
2014
Changes over time in the Chlamydia trachomatis serotype distribution in Finnish women.
Wikström E, Surcel HM, Merikukka M, Ohman H, Namujju PB, Tasanen K, Tiitinen A, Paavonen J, Lehtinen M.
Prevention of HPV disease burden.
Lehtinen M, Nieminen P, Apter D, Paavonen J.
2013
Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.
Vänskä S, Auranen K, Leino T, Salo H, Nieminen P, Kilpi T, Tiihonen P, Apter D, Lehtinen M.
Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M, Dillner J.
2012
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination
Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, Dubin G, Lehtinen M.
Cross-protection is crucial for prophylactic HPV vaccination.
Lehtinen M.
Sound efficacy of prophylactic HPV vaccination: Basics and implications.
Lehtinen M, Paavonen J.
2011
Impact of HPV vaccination on young women's quality of life - a five year follow-up study.
Woodhall S, Eriksson T, Nykänen AM, Huhtala H, Rissanen P, Apter D, Paavonen J, Lehtinen M.
The ethics of implementing human papillomavirus vaccination in developed countries.
Malmqvist E, Helgesson G, Lehtinen J, Natunen K, Lehtinen M.
2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.
Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses
Laukkanen P, Läärä E, Koskela P, Pukkala E, Virkkunen H, Lehtinen M
2009
Papilloomaviruksen ja klamydian torjunnan vaikuttavuus
Lehtinen M, Eriksson T, Apter D, Paavonen J.
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.
Impact of human papillomavirus vaccination depends on effective vaccination strategy.
Lehtinen M, Paavonen J.
2008
Strengthening prevention programs to eliminate cervical cancer in the Nordic countries
Dillner L, Pagliusi S, Bray F, Lorincz A, Kjaer SK, Anttila A, Iversen OE, Dillner J, Lehtinen M, Paavonen J.
Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003.
Lyytikäinen E, Kaasila M, Koskela P, Lehtinen M, Patama T, Pukkala E, Tasanen K, Surcel HM, Paavonen J.
2007
Geographic distribution of cervical cancer-associated human leucocyte antigens and cervical cancer incidence in Finland.
Castro FA, Haimila K, Pasanen K, Kaasila M, Patama T, Partanen J, Surcel HM, Pukkala E, Lehtinen M.
Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland.
Woodhall SC, Lehtinen M, Verho T, Huhtala H, Hokkanen M, Kosunen E.
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers.
Pukkala E, Andersen A, Berglund G, Gislefoss R, Gudnason V, Hallmans G, Jellum E, Jousilahti P, Knekt P, Koskela P, Kyyrönen PP, Lenner P, Luostarinen T, Löve A, Ogmundsdóttir H, Stattin P, Tenkanen L, Tryggvadóttir L, Virtamo J, Wadell G, Widell A, Lehtinen M, Dillner J.